Close Menu

long fragment read technology

The sequencing company reported preliminary fourth quarter revenues of $27 million and said it currently has $318 million in cash and investments.

In Nature this week: a new method for high-throughput amplicon sequencing, and more.

Some core labs are expecting long waitlists in 2021 as PacBio's HiFi reads draw interest from researchers looking to put together whole genomes.

The methods, both published in Nature Biotechnology this week, result in completely phased haplotypes, without the need for sequencing parental samples.

In their first conference call with investors, PacBio's new CEO and CFO laid out a strategic plan for the company as it weathers the COVID-19 pandemic.

Instrument revenues for the Menlo Park, California-based sequencing firm fell due to the COVID-19 pandemic, but consumables sales grew 16 percent.

The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.

The organizations will apply PacBio's HiFi sequencing to a rare disease cohort whose genomes have not yet yielded causal variants by other methods.

In Nature this week: molecular profiling platform identifies treatments for pediatric cancer cases, metaFlye algorithm addresses challenges of long-read metagenomic assembly, and more.

The single-molecule sequencing firm is skipping a beta testing program for its new sequencer, which should be available by the end of the year.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.